AQUA 25: USE OF PREDNISONE FOR CRPC PATIENTS ON ABIRATERONE

STEWARD

AMERICAN UROLOGICAL ASSOCIATION

DESCRIPTION

Percentage of patients who are receiving abiraterone who are also receiving prednisone.

TYPE

Process

DATA SOURCE

Electronic Health Records: AQUA Registry Data

NUMERATOR STATEMENT

Patients receiving prednisone

DENOMINATOR STATEMENT

Patients with advanced prostate cancer on abiraterone

DENOMINATOR DETAILS

List Denominator Codes

DENOMINATOR EXCLUSIONS/EXCEPTIONs

RATIONALE

Patients on abiraterone should also receive prednisone. Abiraterone blocks production of not only androgen but also corticosteroids but also not mineralocorticoids. Thus, prednisone has two functions – 1) to replace the corticosteroids that the body cannot make and 2) to lower ACTH levels and thereby suppress the excess mineralocorticoids that can be made. Without prednisone, the side effects of abiraterone are much higher and alter the risk-benefit ratio of the drug.

RISK ADJUSTMENT

No

INVERSE MEASURE

No

ALGORITHM

COPYRIGHT/DISCLAIMER

AMERICAN UROLOGICAL ASSOCIATION